Editorial

View All
Your Trusted Source for Healthcare News
Editorial Get Oncology Dosing Right Early: A Sponsor Playbook

Biotech and pharma sponsors struggle when dose decisions are made late, rest on narrow evidence, or require protocol amendments that burn time and capital.The fastest way to change that trajectory is…

How AI Is Transforming Healthcare Operations: From Electronic Records to Smarter Care Delivery
EditorialHow AI Is Transforming Healthcare Operations: From Electronic Records to Smarter Care Delivery

A clinician spends nearly two hours on documentation for every hour of direct patient care. This

How Healthcare Leaders Can Turn AI Into a Clinical Advantage in Oncology
EditorialHow Healthcare Leaders Can Turn AI Into a Clinical Advantage in Oncology

Oncology does not have a data problem. It has a decision latency problem that keeps insights

Predictive Public Health With Random Forests, Done Right
EditorialPredictive Public Health With Random Forests, Done Right

Most public health models explain yesterday's outbreak. Leaders need systems that flag risk

Breaking Barriers: AI's Role in Improving Healthcare Systems
EditorialBreaking Barriers: AI's Role in Improving Healthcare Systems

Each patient generates over 1,300 data points daily in modern intensive care units. This data surge

View All

Tech & Innovation

View All
View All

Management & Administration

View All
View All
Who Owns the Codes to Your Medical Bills?
Management & Administration Who Owns the Codes to Your Medical Bills?

A growing number of healthcare stakeholders are voicing concerns that the proprietary nature of the CPT system creates an opaque environment that hides the true cost of medical care. This system, known as the Current Procedural Terminology, is maintained by the American Medical Association, a

Capital Concentration Drives European HealthTech Funding
Management & AdministrationCapital Concentration Drives European HealthTech Funding

Capital is currently concentrating on high-cost chronic conditions, with cardiovascular disease and

Can LYMPHIR’s Sales Growth Save Citius Pharmaceuticals?
Management & AdministrationCan LYMPHIR’s Sales Growth Save Citius Pharmaceuticals?

Citius Pharmaceuticals is leveraging a staggering 86 percent overall response rate from Phase 1

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later